Pasithea Therapeutics (KTTA) Short Interest Ratio & Short Volume → Tiny AI projects with huge promise hiding in plain sight … (From Weiss Ratings) (Ad) Free KTTA Stock Alerts $6.65 0.00 (0.00%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Pasithea Therapeutics Short Interest DataCurrent Short Volume10,000 sharesPrevious Short Volume10,000 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$69,200.00Short Interest Ratio / Days to Cover3.0Last Record DateApril 30, 2024Outstanding Shares1,040,000 sharesFloat Size743,600 sharesShort Percent of Float1.34%Today's Trading Volume1,374 sharesAverage Trading Volume8,569 sharesToday's Volume Vs. Average16% Short Selling Pasithea Therapeutics ? Sign up to receive the latest short interest report for Pasithea Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatKTTA Short Interest Over TimeKTTA Days to Cover Over TimeKTTA Percentage of Float Shorted Over Time Ad Banyan Hill PublishingForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadThe AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016.Get the full story here. Pasithea Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202410,000 shares $69,200.00 No Change1.3%3 $6.92 4/15/202410,000 shares $71,500.00 +14.9%1.3%2 $7.15 3/31/20248,700 shares $63,077.61 +3.6%1.2%1 $7.25 3/15/20248,400 shares $58,575.72 -8.7%0.1%0.7 $6.97 2/29/20249,200 shares $73,600.00 +4.6%0.1%0.1 $8.00 2/15/20248,800 shares $62,524.00 -5.4%0.1%0.1 $7.11 Get the Latest News and Ratings for KTTA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20249,300 shares $60,915.00 -31.1%0.1%0.1 $6.55 1/15/202413,500 shares $101,385.00 +29.8%0.1%0.2 $7.51 12/31/202310,400 shares $76,960.00 -98.1%0.1%0.1 $7.40 12/15/2023539,600 shares $188,860.00 +1,652.0%3.6%0.3 $0.35 11/30/202330,800 shares $10,040.80 -13.7%0.2%0.8 $0.33 11/15/202335,700 shares $11,781.00 -2.5%0.2%1.2 $0.33 10/31/202336,600 shares $12,810.00 -13.3%0.2%1 $0.35 10/15/202342,200 shares $18,568.00 +29.5%0.2%0.8 $0.44 9/30/202332,600 shares $15,638.22 -40.0%0.2%0.2 $0.48 9/15/202354,300 shares $27,150.00 -55.7%0.3%0.3 $0.50 8/31/2023122,600 shares $74,234.30 -24.1%0.6%0.6 $0.61 8/15/2023161,500 shares $97,788.25 +111.1%0.8%0.7 $0.61 7/31/202376,500 shares $45,754.65 +4.2%0.4%0.3 $0.60 7/15/202373,400 shares $34,211.74 -26.0%0.4%0.3 $0.47 6/30/202399,200 shares $48,608.00 -32.4%0.5%0.8 $0.49 6/15/2023146,800 shares $67,997.76 +149.2%0.8%1.6 $0.46 5/31/202358,900 shares $20,615.00 -2.0%0.3%0.7 $0.35 5/15/202360,100 shares $21,041.01 +39.4%0.3%1.2 $0.35 4/30/202343,100 shares $15,080.69 +24.9%0.2%0.7 $0.35 4/15/202334,500 shares $13,458.45 +37.5%0.2%0.5 $0.39 3/31/202325,100 shares $9,412.50 -60.8%0.2%0.3 $0.38 3/15/202364,100 shares $30,133.41 +357.9%0.5%0.7 $0.47 2/28/202314,000 shares $6,721.40 +25.0%0.1%0.1 $0.48 2/15/202311,200 shares $6,287.74 -78.8%0.1%0.1 $0.56 1/31/202352,900 shares $37,180.77 -64.2%0.4%0.6 $0.70 1/15/2023147,900 shares $103,027.29 -12.9%1.1%2.1 $0.70 12/30/2022169,800 shares $108,960.66 -13.7%1.3%1.8 $0.64 12/15/2022196,700 shares $155,786.40 -6.2%1.5%1.8 $0.79 11/30/2022209,800 shares $207,743.96 +10.8%1.6%1.9 $0.99 11/15/2022189,300 shares $194,979.00 -16.1%1.5%1.4 $1.03 10/31/2022225,600 shares $245,904.00 -36.8%1.7%0.5 $1.09 10/15/2022356,700 shares $445,875.00 +44.1%2.7%0.7 $1.25 9/30/2022247,600 shares $311,976.00 -17.0%1.7%0.5 $1.26 9/15/2022298,200 shares $357,840.00 +20.2%2.0%0.6 $1.20Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016.Get the full story here. KTTA Short Interest - Frequently Asked Questions What is Pasithea Therapeutics' current short interest? Short interest is the volume of Pasithea Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 10,000 shares of KTTA short. 1.34% of Pasithea Therapeutics' shares are currently sold short. Learn More on Pasithea Therapeutics' current short interest. What is a good short interest ratio for Pasithea Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KTTA shares currently have a short interest ratio of 3.0. Learn More on Pasithea Therapeutics's short interest ratio. What is a good short interest percentage for Pasithea Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.34% of Pasithea Therapeutics' floating shares are currently sold short. What is Pasithea Therapeutics' float size? Pasithea Therapeutics currently has issued a total of 1,040,000 shares. Some of Pasithea Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Pasithea Therapeutics currently has a public float of 743,600 shares. How does Pasithea Therapeutics' short interest compare to its competitors? 1.34% of Pasithea Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Pasithea Therapeutics: Shuttle Pharmaceuticals Holdings, Inc. (0.74%), Tenax Therapeutics, Inc. (1.20%), Cadrenal Therapeutics, Inc. (0.80%), Vaccinex, Inc. (2.40%), Hepion Pharmaceuticals, Inc. (1.19%), Biofrontera Inc. (0.75%), Pulmatrix, Inc. (0.08%), ASLAN Pharmaceuticals Limited (4.12%), Ainos, Inc. (2.12%), Virios Therapeutics, Inc. (1.24%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Pasithea Therapeutics stock? Short selling KTTA is an investing strategy that aims to generate trading profit from Pasithea Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Pasithea Therapeutics? A short squeeze for Pasithea Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KTTA, which in turn drives the price of the stock up even further. How often is Pasithea Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KTTA, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: SHPH Short Squeeze TENX Short Squeeze CVKD Short Squeeze VCNX Short Squeeze HEPA Short Squeeze BFRI Short Squeeze PULM Short Squeeze ASLN Short Squeeze AIMD Short Squeeze VIRI Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KTTA) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCharles Payne Demystifies OptionsUnstoppable Prosperity